BIO-Europe Spring 2019: Adrenomed’s Hein On Sepsis And Beyond

 
• By Mike Ward

Adrenomed’s chief business officer Frauke Hein explained to Mike Ward how the company has moved from establishing a diagnostic marker for septic shock to developing a therapeutic candidate.

Video interview
Adrenomed's lead program is in sepsis

Germany’s Adrenomed has set itself the goal of cutting the death rate from sepsis by 50%. It is awaiting results from a 300-patient proof of concept Phase II study of its first-in-class monoclonal antibody adrecizumab later this year, after successfully clearing an interim analysis. Chief business officer Frauke Hein discusses the company’s work in septic shock, and explains how its focus on targeting endothelial dysfunction and rescuing vascular integrity lends itself to other diseases, such as acute heart failure.

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.